Oramed snags Israeli government grant for insulin pill; FDA clears Providence cervical delivery implant;

> Israeli oral insulin company Oramed ($ORMP) pulled in a government grant from the Office of the Chief Scientist for $265,000 to support R&D and clinical studies for its insulin pill ORMD-0801. Release

> Providence Medical Technology snagged 510(k) clearance for its PMT Cervical Cage, a minimally invasive implant and drug-delivery platform for cervical fusion procedures. Release

> Depomed ($DEPO) received a complete response letter from the FDA saying the agency would not approve the application for the company's investigational oral menopause treatment SEFELSA, and Depomed will no longer continue to invest in it. Release

> Genoa Pharmaceuticals worked with researchers at McMaster University to demonstrate that an inhaled treatment for pulmonary fibrosis works better in vivo than oral therapy. Release

> BD Medical launched its BD Neopak, a glass prefillable syringe system that eliminates glass-to-glass contact, resulting in fewer visual defects and increased glass strength, and has reduced silicone levels. Item

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.